Alvocidib
- Generic Name
- Alvocidib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C21H20ClNO5
- CAS Number
- 146426-40-6
- Unique Ingredient Identifier
- 45AD6X575G
- Background
Alvocidib is a synthetic flavonoid based on an extract from an Indian plant for the potential treatment of cancer. It works by inhibiting cyclin-dependent kinases, arresting cell division and causing apoptosis in non-small lung cancer cells.
- Indication
Investigated for use/treatment in esophageal cancer, leukemia (lymphoid), lung cancer, liver cancer, and lymphoma (unspecified).
- Associated Conditions
- -
- Associated Therapies
- -
A Study of DSP-2033 (Alvocidib) in Patients With Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2018-06-20
- Last Posted Date
- 2022-04-12
- Lead Sponsor
- Sumitomo Pharma Co., Ltd.
- Target Recruit Count
- 10
- Registration Number
- NCT03563560
- Locations
- π―π΅
Fukui University Hospital, Yoshida-gun, Fukui, Japan
π―π΅Chugoku Central Hospital, Fukuyama, Hiroshima, Japan
π―π΅Hokkaido University Hospital, Sapporo, Hokkaido, Japan
A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- First Posted Date
- 2018-02-22
- Last Posted Date
- 2022-02-01
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 36
- Registration Number
- NCT03441555
- Locations
- π©πͺ
Univ Klinik Eppendorf Hamburg /ID# 168633, Hamburg, Germany
πΊπΈNYU Langone Medical Center /ID# 201559, New York, New York, United States
πΊπΈUniversity of Pittsburgh Medic /ID# 170790, Pittsburgh, Pennsylvania, United States
Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML).
- Conditions
- Interventions
- First Posted Date
- 2017-10-02
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT03298984
- Locations
- πΊπΈ
Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
πΊπΈUniversity of North Carolina, Chapel Hill, North Carolina, United States
πΊπΈColumbia University, New York, New York, United States
Alvocidib Biomarker-driven Phase 2 AML Study
- Conditions
- Interventions
- First Posted Date
- 2015-08-11
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 104
- Registration Number
- NCT02520011
- Locations
- πΊπΈ
Honor Health Research Institute, Scottsdale, Arizona, United States
πΊπΈMayo Clinic Florida, Jacksonville, Florida, United States
πΊπΈMorristown Cancer Center, Morristown, New Jersey, United States
Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
- Conditions
- Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)Adult Erythroleukemia (M6a)Adult Pure Erythroid Leukemia (M6b)Secondary Acute Myeloid LeukemiaUntreated Adult Acute Myeloid LeukemiaAcute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic SyndromeAdult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloblastic Leukemia Without Maturation (M1)
- Interventions
- First Posted Date
- 2011-05-09
- Last Posted Date
- 2017-07-31
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 172
- Registration Number
- NCT01349972
- Locations
- πΊπΈ
Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States
πΊπΈMayo Clinic Scottsdale-Phoenix, Scottsdale, Arizona, United States
πΊπΈJohns Hopkins University/Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
Irinotecan Hydrochloride With or Without Alvocidib in Treating Patients With Advanced Stomach or Gastroesophageal Junction Cancer That Cannot Be Removed By Surgery
- Conditions
- Interventions
- First Posted Date
- 2009-10-08
- Last Posted Date
- 2014-05-26
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 19
- Registration Number
- NCT00991952
- Locations
- πΊπΈ
University of Michigan, Ann Arbor, Michigan, United States
πΊπΈUC Davis Comprehensive Cancer Center, Sacramento, California, United States
πΊπΈMemorial Sloan-Kettering Cancer Center, New York, New York, United States
Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic SyndromeAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Pure Erythroid Leukemia (M6b)Secondary Acute Myeloid LeukemiaUntreated Adult Acute Myeloid LeukemiaAdult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Interventions
- First Posted Date
- 2008-11-21
- Last Posted Date
- 2018-08-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 78
- Registration Number
- NCT00795002
- Locations
- πΊπΈ
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
πΊπΈJohns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Conditions
- Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myelomonocytic Leukemia (M4)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Recurrent Adult Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2008-03-12
- Last Posted Date
- 2015-07-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 92
- Registration Number
- NCT00634244
- Locations
- πΊπΈ
Northwestern University, Chicago, Illinois, United States
πΊπΈUniversity of Alabama at Birmingham, Birmingham, Alabama, United States
πΊπΈMayo Clinic in Florida, Jacksonville, Florida, United States
Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Relapsed or Refractory Acute Leukemia
- Conditions
- Adult Acute Megakaryoblastic Leukemia (M7)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
- Interventions
- First Posted Date
- 2007-05-07
- Last Posted Date
- 2013-09-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 35
- Registration Number
- NCT00470197
- Locations
- πΊπΈ
Johns Hopkins University, Baltimore, Maryland, United States
πΊπΈUniversity of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
Alvocidib in Patients With Previously Treated Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia Arising From Chronic Lymphocytic Leukemia (CLL)
- First Posted Date
- 2007-04-23
- Last Posted Date
- 2013-02-12
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 165
- Registration Number
- NCT00464633
- Locations
- πΊπΈ
Sanofi-Aventis Investigational Site Number 840023, Ann Arbor, Michigan, United States
π«π·Sanofi-Aventis Investigational Site Number 250002, Tours, France
πΊπΈSanofi-Aventis Investigational Site Number 840017, Indianapolis, Indiana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.